Corporate | 19 March 2013 15:35
Evotec AG / Key word(s): Miscellaneous
19.03.2013 / 15:35
---------------------------------------------------------------------
Hamburg, Germany - 19 March 2013: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) is going to broadcast its press & analyst conference in Frankfurt
live on the internet. The Management Board will inform you about the FY
2012 results as well as about the status of the discovery alliance business
and the partnerships of the development projects. Moreover, they will
provide the status of 'Action Plan 2016 - Innovation Efficiency' and
present an outlook for fiscal year 2013. The conference will be held in
English.
Webcast details:
Date: Tuesday, 26 March 2013
Time: 09.00 am CET (08.00 am GMT/04.00 am EDT)
To join the audio webcast and to access the presentation slides you will
find a link on our home page www.evotec.com shortly before the event.
For those who prefer to listen to the presentation via phone, please dial:
From Germany: +49 (0)69 20 17 44 210
From UK: +44 207 153 9154
From USA: +1 877 423 0830
Access Code: 638618#
The on-demand version of the webcast will be available on our website:
www.evotec.com >Investors> Events> Financial Calendar.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, MedImmune/AstraZeneca and Ono Pharmaceutical.
In addition, the Company has existing development partnerships and product
candidates both in clinical and preclinical development. These include
partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in
the field of diabetes and with Roche in the field of Alzheimer's disease.
For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
End of Corporate News
---------------------------------------------------------------------
19.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
204426 19.03.2013